In comparison with the base model for mortality with cTnI, the prognostic accuracy of the model with hs-cTnT ( Table 2 ) was improved modestly (AUC 66.1% and AUC 69.4%, respectively, P ¼ .03) with a 9.0% IDI (P < .001) and 13.6% NRI (P < .001). In contrast, there was no increase in prognostic accuracy when cTnI and hs-cTnT were both added to the base model for mortality (AUC 69.4% and AUC 69.2%, respectively, P ¼ .9), although there was continued IDI (9.0%, P < .001) and NRI (3.6%, P < .001).
Circulating hs-cTnT and Mortality in the Detectable cTnI Subgroup
In the subgroup with detectable cTnI (n ¼ 302), cTnI and hs-cTnT were correlated (Spearman's rho 0.74, P < .0001). The highest hs-cTnT tertile was associated with a 2.1-fold increase in 5-year mortality risk when compared with the lowest hs-cTnT tertile (HR 2.1; 95% CI, 1.4-3.3; P ¼ .0009, Figure 4 ). After multivariate adjustment for traditional risk factors, the association between high hs-cTnT and mortality persisted (HR 2.0; 95% CI, 1.3-3.2; P ¼ .003). In a sensitivity analysis with additional adjustment for hypertension history and coronary artery disease history, the association between high hs-cTnT and mortality persisted (HR 1.96; 95% CI, 1.22-3.20, P ¼ .005). In further sensitivity analyses with additional adjustment for eGFR to traditional risk factors, there was a similar association with high hs-cTnT and mortality (HR 2.1; 95% CI, 1.1-4.0; P ¼ .03), but the effects were not significant when NT-proBNP was further added to the model.
In comparison with the base model for mortality with cTnI (AUC 70.8%), the prognostic accuracy of base model with hs-cTnT or with both hs-cTnT and cTnI was not different (AUC 71.2%, P ¼ .8 and AUC 70.9%, P ¼ .9; respectively; Table 2 ). However, both models had sustained IDI at 11.0% (P < .001, for both) and had 8.1% (P < .001) and 6.8% (P < .001) event-specific NRI, Figure 3 (A) Kaplan Meier estimates of 5 year survival rates according to cTnI levels above or below the limit of detection (n ¼ 504). P value calculated by the log rank test. (B) Kaplan Meier estimates of 5 year survival rates according to hs cTnT levels (n ¼ 504). P value calculated by the log rank test. cTnI ¼ cardiac troponin I; hs cTnT ¼ high sensitivity cardiac troponin T. eGFR. However, while the analytical performance of hscTnT appeared superior, there was overlap in prognostic accuracy of hs-cTnT in subjects with detectable cTnI. These findings highlight the prognostic value of highly sensitive cTn assays in the setting of heart failure, yet also point to the need for future studies to better determine whether the improved sensitivity of cTn assays can translate into incremental clinical benefits.
In contrast to the general population, 15, 16 patients with chronic heart failure have more prevalent detectable cTn. The etiology of cTn release in chronic heart failure patients is unclear and likely multifactorial. It may be triggered by acute and chronic myocardial stress, chronic sub-clinical sub-endocardial ischemia, or direct cardiomyocyte injury. 17 It also may result from increased apoptosis in heart failure, 5 thus representing increased cardiomyocyte turnover, which may be indicative of progressive myocardial dysfunction. In heart failure patients, circulating cTn levels have prognostic value independent of renal function 18 and natriuretic peptide levels, 19 in heart failure with either reduced or preserved left ventricular ejection fraction, 20 and in the elderly.
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Our results support and add to the growing body of evidence that detectable cTn at any level of assay sensitivity has strong prognostic utility in patients with heart failure. [7] [8] [9] [10] [11] [21] [22] [23] As hypothesized, increased circulating hscTnT was independently and incrementally associated with incident 5-year mortality after multivariate adjustment for strong heart failure risk factors. Previously, a retrospective analysis of the Valsartan Heart Failure Trial (Val-HeFT) found a similarly high portion (92.0%; 3728/4053) had detectable hs-cTn by an older assay. 7 In this and another analysis that pooled the Val-HeFT and Gruppo Italiano per lo Studio della Sproavvivenza nell'Insufficienza CardiacaHeart Failure cohorts, 9 higher circulating hs-cTn was associated with both incident heart failure hospitalization and mortality, and improved the prognostic accuracy of subjects' clinical risk factors in addition to B-type natriuretic peptide. Unlike our analysis, however, no head-to-head comparisons were made between circulating cTn by both assays.
What is unclear from previous chronic heart failure cohorts, where circulating cTn is measured by both assays, 7,9 is determining whether there is a clinical advantage to prognosticate by measuring hs-cTn when cTn may be detectable by a standard assay; and if such an advantage is related to the increased sensitivity of the hs-cTn assay. In our cohort, circulating hs-cTnT had higher prognostic accuracy when compared with circulating cTnI, thus supporting the use of measuring cTn by high-sensitivity assays instead of standard assays in chronic heart failure. However, there was overlap in incident mortality discrimination of measuring circulating hs-cTnT if cTnI was detectable, which questions the use of measuring cTn by a high-sensitivity assay if cTn is in the detectable range of the standard assay. Therefore, these results suggest that circulating hs-cTn may have a higher prognostic accuracy primarily as a result of their increased sensitivity. 6 In other words, when patients present with a quantifiable cTn level based on standard assay, there appears to be an incremental benefit to stratify risk, although a limited change in endpoint prediction (discrimination) with the addition of a highly sensitive cTn test based on our findings. Risk calibration and endpoint discrimination are often discordant for major disease factors, and excessive reliance on the AUC has been discouraged previously. 24 One of the biggest advantages of utilizing a more sensitive assay is to expand the lower range of quantifiable cTn. From head-to-head comparisons in non-heart-failure populations, circulating cTn measured by high-sensitivity assays identifies a larger population with cardiac risk factors, structural cardiac abnormalities, increased risk of incident heart failure, and adverse cardiac events than circulating cTn measured by standard assays. 15, 16, 25 In the undetectable cTnI subgroup, very low levels of circulating hs-cTnT were still associated with 5-year mortality (Figure 4) . This suggests that very low circulating hs-cTnT, well below the assay's 99 th percentile cut-off, yields prognostically important information in patients with heart failure and are supported by similar findings in previous heart failure cohorts. 7, 9, 11 Taken in aggregate, there appears to be clinically important information embedded in very low cTn levels, thus questioning the clinical utility of using a 99 th percentile cut-off for "normal" in patients with heart failure. Although we describe associations of very low cTn levels with age, NT-proBNP, and renal function, further studies are needed to determine the etiology of cTn release and whether similarly low-risk chronic heart failure populations need further risk stratification.
Furthermore, high-sensitivity cTn levels may be viable therapeutic targets for medication titration in similarly low-risk patients with chronic heart failure. In patients with non-ST-segment elevation acute coronary syndromes, antiplatelet therapy escalation guided by circulating cTn has been shown to favorably influence treatment outcomes. 26 Indeed, detectable cTn levels in the setting of receiving high-dose chemotherapy have already demonstrated the ability to identify a patient population with risk of progressive deterioration of cardiac dysfunction that may be ameliorated by initiation of angiotensin-converting enzyme inhibitors. 27 In heart failure, however, whether adjusting chronic heart failure therapy (beta-blockers, reninangiotensin blockers, or mineralocorticoid receptor antagonists) affects serial hs-cTn levels is unknown. Yet, because changing high-sensitivity cTn levels are associated with prognosis in chronic heart failure, 9, 28 future studies to assess associations of medical therapy adjustments and changes in high-sensitivity cTn levels are therefore warranted.
These results must be interpreted in the context of several limitations in our study design. Because cTn levels were measured at only one point in time, we were unable to examine the variability and prognostic value of changing cTn levels by 2 cTn assays over time or the impact of different therapies in the interim. We cannot exclude the presence of selection bias for those undergoing coronary angiography for further evaluation and management of heart failure at a tertiary care center, even though based on baseline clinical characteristics, our cohort is relatively representative of a contemporary patient population with chronic heart failure with both preserved and reduced left ventricular ejection fraction, and we excluded all patients with any suspicion or clinical history of acute coronary syndromes. However, limitations to external validity include a large proportion of patients in this analysis with ischemic cardiomyopathy. Indeed, many noncardiac conditions are associated with detectable circulating troponin, 29 such as sepsis, pulmonary embolism, chronic kidney disease, and myocarditis. With the exception of renal dysfunction, the incidence of these and other acute conditions where troponin is associated with mortality was likely very low as subjects in this study were included before elective coronary angiography. Nevertheless, based on these analyses and because we are in the era when recognizing the potential harms for excessive diagnostics are at the forefront, further investigations continuing to clarify clinical utilities of cTn measured by highly sensitive assays are warranted.
CONCLUSION
In patients with chronic heart failure, when compared with standard assays, high-sensitivity assays identify more patients with detectable circulating cTn. Although plasma hs-cTnT levels provide incremental and independent prognostic value and increased prognostic accuracy in patients with chronic heart failure, there is overlap in this value when both assays measure cTn in the detectable range.
